# A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

> **NCT07174310** · PHASE3 · RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 900 (estimated)

## Conditions studied

- Parkinson's Disease

## Interventions

- **DRUG:** Prasinezumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07174310
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-24
- **Primary completion:** 2029-06-30
- **Final completion:** 2031-06-30
- **Target enrollment:** 900 (ESTIMATED)
- **Last updated:** 2026-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07174310

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07174310, "A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07174310. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*